Incidence of tuberculosis in people living with the human immunodefi ciency virus in Saudi Arabia

International Journal of Tuberculosis and Lung Disease

Volumn 14, Issue 5, 2010, Pages 600-603

  Omair, M A ^a   Al Ghamdi, A A ^a   Alrajhi, A A ^a  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

Epidemiology; HIV; Incidence; Saudi Arabia; Tuberculosis

Indexed keywords

TUBERCULOSTATIC AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AIDS PATIENT; ARTICLE; CAUSE OF DEATH; CD4 LYMPHOCYTE COUNT; CENTRAL NERVOUS SYSTEM TUBERCULOSIS; EARLY DIAGNOSIS; EXTRAPULMONARY TUBERCULOSIS; FEMALE; FOLLOW UP; HOSPITAL INFECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INFECTION RATE; LONGITUDINAL STUDY; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; SAUDI ARABIA; TUBERCULOUS LYMPHADENITIS; UROGENITAL TUBERCULOSIS;

ADOLESCENT; ADULT; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; INCIDENCE; LONGITUDINAL STUDIES; MALE; SAUDI ARABIA; TREATMENT OUTCOME; TUBERCULOSIS; YOUNG ADULT;

EID: 77950899093     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Gillini L, Seita A. Tuberculosis and HIV in the Eastern Mediterranean Region. East Mediterr Health J 2002; 8: 699-705. (Pubitemid 40326278)
2. World Health Organization. Global tuberculosis control: surveillance, planning, f nancing. WHO/HTM/TB/2007.376. Geneva, Switzerland: WHO, 2007.
3. World Health Organization. Global tuberculosis control 2009: epidemiology, strategy, f nancing. WHO/HTM/TB/2009.411. Geneva, Switzerland: WHO, 2009.
4. El-Sadr W M, Tsiouris S J. HIV-associated tuberculosis: diagnostic and treatment challenges. Semin Respir Crit Care Med 2008; 29: 525-531.
5. Mendelson M. Diagnosing tuberculosis in HIV-infected patients: challenges and future prospects. Br Med Bull 2007; 81-82: 149-165. (Pubitemid 351194481)
6. Antonucci G, Girardi E, Raviglione M C, Ippolito G. Risk factors for tuberculosis in HIV-infected persons. A prospective cohort study. The Gruppo Italiano di Studio Tubercolosi e AIDS (GISTA). JAMA 1995; 274: 143-148.
7. Daley C L, Small P M, Schecter G F, et al. An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodef ciency virus. An analysis using restriction-fragment-length polymorphisms. N Engl J Med 1992; 326: 231-235.
8. Davies P D. The world-wide increase in tuberculosis: how demographic changes, HIV infection and increasing numbers in poverty are increasing tuberculosis. Ann Med 2003; 35: 235-243.
9. Vermund S H, Yamamoto N. Co-infection with human immuno-def ciency virus and tuberculosis in Asia. Tuberculosis (Edinb) 2007; 87 (Suppl 1): S18-S25. (Pubitemid 47223827)
10. Centers for Disease Control. 1993 Revised Classif cation system for HIV infection and expanded surveillance case def ni-tion for AIDS among adolescents and adults. MMWR 1992; 41 (RR-17).
11. Ministry of Health. Health statistical year book 1428 H (2007). Riyadh, Saudi Arabia: Ministry of Health; 2008.
12. Ackah A N, Coulibaly D, Digbeu H, et al. Response to treatment, mortality and CD4 lymphocyte counts in HIV-infected persons with tuberculosis in Abidjan, Cote d'Ivoire. Lancet 1995; 345: 607-610.
13. Badri M, Wilson D, Wood R. Effect of highly active antiretro-viral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet 2002; 359: 2059-2064. (Pubitemid 34680968)
14. Girardi E, Antonucci G, Vanacore P, et al. Impact of combination antiretroviral therapy on the risk of tuberculosis among persons with HIV infection. AIDS 2000; 14: 1985-1991.
15. Jones J L, Hanson D L, Dworkin M S, De Cock K M. HIV-a ssociated tuberculosis in the era of highly active antiretroviral therapy. The Adult/Adolescent Spectrum of HIV Disease Group. Int J Tuberc Lung Dis 2000; 4: 1026-1031.
16. Santoro-Lopes G, de Pinho A M, Harrison L H, Schechter M. Reduced risk of tuberculosis among Brazilian patients with advanced human immunodef ciency virus infection treated with highly active antiretroviral therapy. Clin Infect Dis 2002; 34: 543-546. (Pubitemid 34112278)
17. Alrajhi A A, Halim M A, Al-Abdely H M. Presentation and reasons for HIV-1 testing in Saudi Arabia. Int J STD AIDS 2006; 17: 806-809.
18. American Thoracic Society. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR 2000; 49 (RR-6): 1-51.
19. Golub J E, Astemborski J, Ahmed M, et al. Long-term effectiveness of diagnosing and treating latent tuberculosis infection in a cohort of HIV-infected and at-risk injection drug users. J Acquir Immune Def c Syndr 2008; 49: 532-537.
20. Kaplan J E, Benson C, Holmes K H, Brooks J T, Pau A, Masur H. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR 2009; 58 (RR-4): 1-207.
21. Aichelburg M C, Rieger A, Breitenecker F, et al. Detection and prediction of active tuberculosis disease by a whole-blood i nterferon-gamma release assay in HIV-1-infected individuals. Clin Infect Dis 2009; 48: 954-962.
22. Stephan C, Wolf T, Goetsch U, et al. Comparing Quanti-FERON-tuberculosis Gold, T-SPOT tuberculosis and tuberculin skin test in HIV-infected individuals from a low prevalence tuberculosis country. AIDS 2008; 22: 2471-2479.